PRA Health Sciences Inc (PRAH) Shares Bought by Credit Suisse AG

Credit Suisse AG lifted its position in PRA Health Sciences Inc (NASDAQ:PRAH) by 20.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 605,977 shares of the medical research company’s stock after buying an additional 102,041 shares during the quarter. Credit Suisse AG’s holdings in PRA Health Sciences were worth $66,773,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of PRAH. Twin Tree Management LP purchased a new stake in PRA Health Sciences during the 2nd quarter worth about $120,000. Price Capital Management Inc. purchased a new stake in PRA Health Sciences during the 3rd quarter worth about $121,000. Mount Yale Investment Advisors LLC increased its holdings in PRA Health Sciences by 103.6% during the 2nd quarter. Mount Yale Investment Advisors LLC now owns 1,704 shares of the medical research company’s stock worth $159,000 after purchasing an additional 867 shares during the period. Parallel Advisors LLC increased its holdings in PRA Health Sciences by 930.9% during the 3rd quarter. Parallel Advisors LLC now owns 1,804 shares of the medical research company’s stock worth $199,000 after purchasing an additional 1,629 shares during the period. Finally, Fox Run Management L.L.C. purchased a new stake in PRA Health Sciences during the 2nd quarter worth about $201,000.

Several equities research analysts have weighed in on the company. BidaskClub downgraded PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 16th. SunTrust Banks upped their price target on PRA Health Sciences to $120.00 and gave the stock a “buy” rating in a report on Monday, November 5th. UBS Group assumed coverage on PRA Health Sciences in a report on Tuesday, October 9th. They set a “neutral” rating on the stock. Evercore ISI assumed coverage on PRA Health Sciences in a report on Thursday, October 4th. They set an “inline” rating and a $120.00 price target on the stock. Finally, Robert W. Baird upped their price target on PRA Health Sciences from $112.00 to $116.00 and gave the stock an “outperform” rating in a report on Tuesday, September 11th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $111.50.

PRAH opened at $101.31 on Friday. PRA Health Sciences Inc has a one year low of $79.00 and a one year high of $112.88. The stock has a market capitalization of $6.38 billion, a PE ratio of 31.66, a price-to-earnings-growth ratio of 1.42 and a beta of 0.73. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 1.22.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings data on Wednesday, October 31st. The medical research company reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.06. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The business had revenue of $717.60 million for the quarter, compared to the consensus estimate of $729.63 million. During the same quarter in the prior year, the business posted $0.88 EPS. The business’s revenue for the quarter was up 23.3% on a year-over-year basis. On average, research analysts expect that PRA Health Sciences Inc will post 3.93 earnings per share for the current year.

WARNING: “PRA Health Sciences Inc (PRAH) Shares Bought by Credit Suisse AG” was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.wkrb13.com/2018/11/25/pra-health-sciences-inc-prah-shares-bought-by-credit-suisse-ag.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: What factors cause inflation to rise?

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply